Dyne Therapeutics (DYN) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 148.5% versus a loss of 26.8%. Over five years, XERS leads with a +682.0% price change compared with +5.4% for DYN. Xeris Biopharma is the larger company by market cap ($3.10 billion vs $2.90 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYN | XERS |
|---|---|---|
| Share price | $15.50 | $16.97 |
| Market cap | $2.90B | $3.10B |
| 1-day change | -3.31% | +2.11% |
| YTD return | -20.76% | +116.18% |
| 1-year return | -26.82% | +148.46% |
| 5-year return | +5.37% | +682.03% |
| Forward P/E | — | 63.64 |
| EPS (TTM) | $-3.62 | $-0.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | $-446.21M | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $27.31 | $17.28 |
| 52-week low | $14.00 | $5.25 |
| Distance from 52-week high | -43.23% | -1.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.48% | +1.89% |
| Average volume | 2.94M | 2.86M |
| Shares outstanding | 187.39M | 182.70M |
| Employees | 322 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed DYN by 175.3 percentage points over the past year.
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
DYN vs XERS FAQ
Which is bigger, Dyne Therapeutics or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $3.10B compared with $2.90B for Dyne Therapeutics (DYN).
Which stock has performed better over the past year, DYN or XERS?
XERS returned +148.46% over the past 12 months, compared with -26.82% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are Dyne Therapeutics and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.